Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study

PHASE4CompletedINTERVENTIONAL
Enrollment

425

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Dyslipidemias
Interventions
DRUG

Atorvastatin

Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group

Trial Locations (20)

705-717

Pfizer Investigational Site, Daegu

135-710

Pfizer Investigational Site, Seoul

602-739

Pfizer Investigational Site, Busan

614-735

Pfizer Investigational Site, Busan

700-712

Pfizer Investigational Site, Daegu

302-718

Pfizer Investigational Site, Daejeon

501-757

Pfizer Investigational Site, Gwangju

503-715

Pfizer Investigational Site, Gwangju

431-070

Pfizer Investigational Site, Gyeonggi-do

463-707

Pfizer Investigational Site, Gyeonggi-do

405-760

Pfizer Investigational Site, Incheon

420-717

Pfizer Investigational Site, Kyunggi-do

110-744

Pfizer Investigational Site, Seoul

110-746

Pfizer Investigational Site, Seoul

120-752

Pfizer Investigational Site, Seoul

134-010

Pfizer Investigational Site, Seoul

136-705

Pfizer Investigational Site, Seoul

137-701

Pfizer Investigational Site, Seoul

138-736

Pfizer Investigational Site, Seoul

143-914

Pfizer Investigational Site, Seoul

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00540293 - Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study | Biotech Hunter | Biotech Hunter